U.S. Health System Needs “Innovation Criteria” To Steer Reimbursement
This article was originally published in The Gray Sheet
Executive SummaryPolicymakers should attempt to define "innovation criteria" to help guide healthcare resources towards more significant technological advances, Johnson & Johnson Biopharmaceuticals Group Chairman Joseph Scodari told the Wharton Health Care Business Conference Feb. 19 in Philadelphia
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.